HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Banner, D. W. Articles by Hadvary, P. Search for Related Content PubMed PubMed Citation Articles by Banner, D. W. Articles by Hadvary, P. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 266, Issue 30, 20085-20093, Oct, 1991

Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors

DW Banner and P Hadvary
Pharmaceutical Research Departments, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

The mode of binding of four active-site directed inhibitors to human thrombin has been determined by x-ray crystallographic analysis. The inhibitors studied are benzamidine, PPACK, NAPAP, and MD-805, of which the last three are compounds evolved specifically to inhibit thrombin. Crystal structures were determined in the presence of both the inhibitor and the undecapeptide [des-amino Asp55]hirudin(55-65) which binds distant from the active site. Despite having significantly different chemical structures, NAPAP and MD-805 bind to thrombin in a very similar "inhibitor binding mode" which is not that expected by direct analogy with the binding of substrate. Both inhibitors bind to thrombin in a similar way as to trypsin, but thrombin has an extra loop, the "Tyr-Pro-Pro-Trp loop," not present in trypsin, which gives further binding interactions and is seen to move somewhat to accommodate binding of the different inhibitors. The fact that NAPAP and MD-805 require different stereochemistry for potent inhibition is demonstrated, and its structural basis clarified. The wealth of data on analogs and variants of these lead compounds is shown to be compatible with this inhibitor binding mode.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. S. Henriques, N. Fonseca, and M. J. Ramos On the modeling of snake venom serine proteinase interactions with benzamidine-based thrombin inhibitors Protein Sci., September 1, 2004; 13(9): 2355 - 2369. [Abstract] [Full Text] [PDF]

				S. Sperl, U. Jacob, N. Arroyo de Prada, J. Sturzebecher, O. G. Wilhelm, W. Bode, V. Magdolen, R. Huber, and L. Moroder (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase PNAS, May 9, 2000; 97(10): 5113 - 5118. [Abstract] [Full Text] [PDF]

				V. Nienaber, J. Wang, D. Davidson, and J. Henkin Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite J. Biol. Chem., March 15, 2000; 275(10): 7239 - 7248. [Abstract] [Full Text] [PDF]

				S. Ahmad, A. Ahsan, M. George, O. Iqbal, W. P. Jeske, R. McKenna, B. E. Lewis, J. M. Walenga, and J. Fareed Simultaneous Monitoring of Argatroban and Its Major Metabolite Using an HPLC Method: Potential Clinical Applications Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(4): 252 - 258. [Abstract] [PDF]

				T. Myles, F. C. Church, H. C. Whinna, D. Monard, and S. R. Stone Role of Thrombin Anion-binding Exosite-I in the Formation of Thrombin-Serpin Complexes J. Biol. Chem., November 20, 1998; 273(47): 31203 - 31208. [Abstract] [Full Text] [PDF]

				S. Ahmad, A. Ahsan, O. Iqbal, D. A. Hoppensteadt, B. E. Lewis, J. M. Walenga, and J. Fareed Pharmacokinetics and Pharmacodynamics of Argatroban as Studied by HPLC and Functional Methods: Implications in the Monitoring and Dosage-Optimizations in Cardiovascular Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 1998; 4(4): 243 - 249. [Abstract] [PDF]

				K. Kamata, H. Kawamoto, T. Honma, T. Iwama, and S.-H. Kim Structural basis for chemical inhibition of human blood coagulation factor Xa PNAS, June 9, 1998; 95(12): 6630 - 6635. [Abstract] [Full Text] [PDF]

				A. Hijikata-Okunomiya, Y. Tamao, R. Kikumoto, and S. Okamoto Selective Inhibition of Trypsin by (2R,4R)-4-Phenyl-1-[Nalpha -(7- methoxy-2-naphthalenesulfonyl)-L-arginyl]-2-piperidinecarboxylic Acid J. Biol. Chem., June 16, 2000; 275(25): 18995 - 18999. [Abstract] [Full Text] [PDF]